DYNLL1

Dynein light chain LC8-type 1 P63167 DYL1_HUMAN
Protein Coding Chr 12 12q24.31 Swiss-Prot reviewed Entrez 8655
Mutations
207
CL 56 · Tissue 151
Samples
37
CL 14 · Tissue 23
Peptides
36
unique mutant peptides
Transcripts
9
isoforms mutated

Stats by Source

Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)

How the counts split by source
Stats by Source

Total = all mutations for this gene across every source.

Cell line = COSMIC Cell Lines Project + DepMap + PubMed.

Tissue = COSMIC primary-tissue (patient tumour) samples.

Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.

TotalCell lineTissue
Mutations20756151
Samples371423
Peptides36830

Function

DYNLL1 · Dynein light chain LC8-type 1

Cytoplasmic dyneins are large enzyme complexes with a molecular mass of about 1,200 kD. They contain two force-producing heads formed primarily from dynein heavy chains, and stalks linking the heads to a basal domain, which contains a varying number of accessory intermediate chains. The complex is involved in intracellular transport and motility. The protein described in this record is a light chain and exists as part of this complex but also physically interacts with and inhibits the activity of neuronal nitric oxide synthase. Binding of this protein destabilizes the neuronal nitric oxide synthase dimer, a conformation necessary for activity, and it may regulate numerous biologic processes through its effects on nitric oxide synthase activity. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008].

Isoforms & Proteins

9 transcripts · UniProt mapping is sequence-verified (AA-safe)

About the isoform mapping
Isoforms & Proteins

Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.

The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.

Counts are mutations and unique mutant peptides on each transcript.

TranscriptUniProtMutationsPeptides
ENST00000242577 P63167 32 24
ENST00000392508 P63167 25 23
ENST00000392509 P63167 25 23
ENST00000548342 P63167 25 23
ENST00000549989 P63167 25 23
ENST00000552870 F8VXL2* 21 19
ENST00000548214 F8VRV5* 18 17
ENST00000550178 F8VRV5* 18 17
ENST00000550845 F8VRV5* 18 17

Gene Properties

Type
Protein Coding
Chromosome
12
Cytoband
12q24.31
Entrez ID
Aliases
DLC1DLC8DNCL1DNCLC1LC8LC8a

Recurrent Mutations

All 24 amino-acid changes on canonical ENST00000242577 · needle height = samples · drag the mini-map to zoom

What this lollipop shows
Recurrent Mutations

A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).

X-axis = amino-acid position in the protein.

Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.

The most recurrent changes are labelled; hover any needle for the change, position and counts.

Mutation frequency across cancer types

% of samples with a missense/complex mutation in DYNLL1 · cell line vs tissue

How this frequency is counted
Cancer-type mutation frequency

For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DYNLL1 – counted as distinct samples (a sample counts once no matter how many mutations it has).

Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.

Cancer typeCell linesTissue samples
T-Lymphoblastic Leukemia
2/40 5%
0/0 0%
Endometrial Carcinoma
2/42 5%
1/612 0%
Cervical Carcinoma
0/35 0%
2/422 0%
Neuroendocrine Tumour
2/154 1%
0/577 0%
Ovarian Carcinoma
2/109 2%
1/998 0%
Gastric Carcinoma
2/74 3%
3/1809 0%
Head and Neck Carcinoma
0/85 0%
4/1574 0%
Bladder Carcinoma
0/58 0%
2/956 0%
Small Cell Lung Carcinoma
0/9 0%
1/752 0%
Pancreatic Carcinoma
1/89 1%
1/1611 0%
Melanoma
0/210 0%
2/1899 0%
Prostate Carcinoma
2/13 15%
0/2105 0%
Colorectal Carcinoma
0/143 0%
2/3239 0%
Thyroid Gland Carcinoma
0/45 0%
1/1592 0%
Other Solid Cancers
0/94 0%
1/1515 0%
Breast Carcinoma
0/144 0%
2/3264 0%
Hepatocellular Carcinoma
1/46 2%
0/2210 0%

Mutation Distribution

Where DYNLL1 is mutated · all tissues, split by cell line vs tissue

Mutation counts by tissue
Mutation Distribution

How many mutations in DYNLL1 were found in each tissue, across the whole database.

Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.

This shows the cancer-context where this gene is recurrently altered.

GTEx Expression

Median TPM across 54 healthy tissues

GTEx Portal ↗
About the expression data
GTEx Expression

Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.

Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.

Scroll or drag the mini-axis below the chart to browse all tissues.

Mutations

All 207 mutations in DYNLL1

About the mutation list
Mutations

Every mutation record for this gene, across all samples and sources.

The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).

Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.

IDSampleTranscriptAA Change CDSTypeSourceMutant PeptideWild-type Peptide